Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

Overview of attention for article published in Patient preference and adherence, November 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Citations

dimensions_citation: 96 Dimensions

Readers on

mendeley: 75 Mendeley

Summary News Policy documents Dimensions citations

So far, Altmetric has seen 2 news stories from 1 outlets.

FDA OKs Subcutaneous Actemra

Drugs.com, 22 Oct 2013

Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderately to…

Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis

Drugs.com, 22 Oct 2013

Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderately to…